Vaxcyte CFO surrenders 7,155 shares for taxes

Vaxcyte’s president and CFO reported RSU-related tax withholding of 7,155 shares and now holds stock both directly and through a GRAT entity.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) reported that President and CFO Andrew Guggenhime had 7,155 shares of common stock withheld on September 8, 2026 to cover tax liabilities arising from the vesting of restricted stock units, at a reference price of $60.36 per share. After this tax-withholding disposition, he holds 95,316 shares directly, plus 61,850 shares held indirectly through ALG 2025 GRAT Holdings LLC, a grantor retained annuity trust for which he is annuitant and trustee.

Insider Trade Summary

Tax Withholding: 7,155 shares

Tax Withholding 2 txns

Insider GUGGENHIME ANDREW

Role PRESIDENT AND CFO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	7,155	$60.36	$432K
holding	Common Stock F2	--	--	--

Holdings After Transaction: Common Stock — 95,316 shares (Direct); Common Stock — 61,850 shares (Indirect, See Footnote)

Footnotes (2)

1. F1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
2. F2. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.

Key Figures

Shares surrendered for tax withholding: 7,155 shares Reference price per share: $60.36 per share Direct holdings after transaction: 95,316 shares +1 more

4 metrics

Shares surrendered for tax withholding 7,155 shares Common stock withheld on September 8, 2026 to cover RSU tax obligations

Reference price per share $60.36 per share Value used for the 7,155-share tax-withholding disposition on September 8, 2026

Direct holdings after transaction 95,316 shares Vaxcyte common stock directly owned by Andrew Guggenhime following the tax-withholding event

Indirect holdings through GRAT entity 61,850 shares Shares held by ALG 2025 GRAT Holdings LLC associated with a grantor retained annuity trust

Key Terms

restricted stock units, grantor retained annuity trust, Form 4

3 terms

restricted stock units financial

"tax withholding obligations realized upon the vesting of RSUs"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grantor retained annuity trust financial

"owned by a grantor retained annuity trust, of which the Reporting Person is"

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

Form 4 regulatory

"The Vaxcyte Form 4 reports this insider transaction and resulting holdings"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did Vaxcyte (PCVX) disclose for Andrew Guggenhime?

Vaxcyte disclosed that President and CFO Andrew Guggenhime had 7,155 shares of common stock surrendered on September 8, 2026 to satisfy tax withholding obligations triggered by the vesting of RSUs, at a reference price of $60.36 per share.

Was the Vaxcyte (PCVX) Form 4 transaction an open-market sale?

No. The 7,155 shares were surrendered to Vaxcyte to cover tax withholding on vested RSUs, as stated in the footnote, rather than sold in an open-market transaction.

How many Vaxcyte (PCVX) shares does Andrew Guggenhime now hold directly?

After the reported tax-withholding disposition, Andrew Guggenhime directly holds 95,316 shares of Vaxcyte common stock, according to the Form 4.

What indirect Vaxcyte (PCVX) holdings does Andrew Guggenhime report?

He reports indirect ownership of 61,850 shares of Vaxcyte common stock held by ALG 2025 GRAT Holdings LLC, which is owned by a grantor retained annuity trust for which he is the annuitant and trustee.

Was the Vaxcyte (PCVX) Form 4 transaction under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed, and there is no footnote stating the transaction was made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 05:54 PM Accepted by SEC EDGAR 09/09/2026 - 05:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GUGGENHIME ANDREW

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		F		7,155(1)	D	$60.36	95,316	D
Common Stock								61,850	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

2. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.

Remarks:

	Andrew Guggenhime, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)